Harmony Biosciences Holdings, Inc. (HRMY)
Automate Your Wheel Strategy on HRMY
With Tiblio's Option Bot, you can configure your own wheel strategy including HRMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HRMY
- Rev/Share 12.9969
- Book/Share 12.5724
- PB 2.7441
- Debt/Equity 0.0243
- CurrentRatio 3.6701
- ROIC 0.1938
- MktCap 1981138350.0
- FreeCF/Share 3.863
- PFCF 8.9486
- PE 12.9466
- Debt/Assets 0.0166
- DivYield 0
- ROE 0.2429
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HRMY | Deutsche Bank | -- | Buy | -- | $55 | Feb. 11, 2025 |
| Initiation | HRMY | H.C. Wainwright | -- | Buy | -- | $75 | Dec. 17, 2024 |
| Resumed | HRMY | Raymond James | -- | Outperform | -- | -- | Oct. 10, 2024 |
| Initiation | HRMY | UBS | -- | Buy | -- | $56 | Sept. 10, 2024 |
News
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q1 2025 Earnings Call May 6, 2025 8:30 AM ET Company Participants Brennan Doyle - Head, Investor Relations Jeffrey Dayno - President and Chief Executive Officer Adam Zaeske - Chief Commercial Officer Kumar Budur - Chief Medical and Scientific Officer Sandip Kapadia - Chief Financial Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities David Amsellem - Piper Sandler Ami Fadia - Needham Patrick Trucchio - H.C. Wainwright David Hoang - Deutsche Bank Ash Verma - UBS Jason Gerberry - Bank of America Charles Duncan - Cantor Fitzgerald Operator Good morning.
Read More
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.67 per share a year ago.
Read More
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, on its way to a potential $1B+ opportunity in narcolepsy alone and poised for additional growth from its next-gen pitolisant development programs. The company has demonstrated four consecutive years of profitability and has grown its cash and investments position to over $600M. “Building off of our strong fou.
Read More
Why Harmony Biosciences (HRMY) Could Beat Earnings Estimates Again
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out
Published: April 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Read More
Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Stockholders to Inquire about Securities Investigation
Published: March 31, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Stockholders to Learn More About the Investigation
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Investors to Inquire about Securities Investigation
Published: March 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Reach Out
Published: March 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
Published: March 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
HRMY Down 10.8% in Six Months: How Should You Play the Stock?
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
A recent regulatory setback has hit Harmony Biosciences stock. We recommend prospective investors to wait for a while before turning positive.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY)Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Harmony and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Read More
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Harmony Biosciences (HRMY) Upgraded to Strong Buy: Here's Why
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
Published: February 19, 2025 by: Benzinga
Sentiment: Negative
On Wednesday, Harmony Biosciences Holdings, Inc. HRMY received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH).
Read More
HRMY or ONC: Which Is the Better Value Stock Right Now?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and BeiGene, Ltd. (ONC). But which of these two stocks is more attractive to value investors?
Read More
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
About Harmony Biosciences Holdings, Inc. (HRMY)
- IPO Date 2020-08-19
- Website https://www.harmonybiosciences.com
- Industry Biotechnology
- CEO Dr. Jeffrey M. Dayno M.D.
- Employees 268